Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, parallel-group, dose-response study to evaluate the efficacy and safety of 3 fixed doses (50mg Eq [equivalent], 100mg Eq and 150mg Eq) of paliperidone palmitate in subjects with schizophrenia.

X
Trial Profile

A randomized, double-blind, placebo-controlled, parallel-group, dose-response study to evaluate the efficacy and safety of 3 fixed doses (50mg Eq [equivalent], 100mg Eq and 150mg Eq) of paliperidone palmitate in subjects with schizophrenia.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 04 Dec 2018 Results from 4 trials published in the Journal of Clinical Psychiatry
    • 10 Apr 2010 Results published in International Clinical Psychopharmacology.
    • 17 Dec 2009 Actual patient number changed from 11 to 366 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top